Champions Oncology, Inc. (NASDAQ:CSBR) is a key player in the field of translational oncology research. The company specializes in providing comprehensive research and development solutions to biopharmaceutical companies. It leverages a vast bank of clinically relevant patient-derived xenograft models to support its services. CSBR's competitors include other oncology research firms that offer similar services to the biopharmaceutical industry.
On December 15, 2025, CSBR reported earnings per share (EPS) of $0.01, which was below the estimated $0.08. The company's actual revenue was $15 million, falling short of the estimated $16.42 million. Despite this, CSBR achieved a record quarterly service revenue of $14.9 million in Q2 2026, marking an 11% increase in total revenue to $15 million, as highlighted by the company's recent earnings call.
The oncology services segment reported a profit of $7.8 million, with a margin of 52%. This indicates a strong performance in this segment, contributing significantly to the company's overall financial health. Net income for the quarter was $237,000, and the adjusted EBITDA stood at $843,000, reflecting the company's ability to generate earnings before interest, taxes, depreciation, and amortization.
For the first half of fiscal 2026, Champions Oncology's total revenue rose by 5% to $29 million. The oncology services profit for this period was $13.8 million, with a margin of 47%, and the adjusted EBITDA was $962,000. CEO Robert Brainin expressed confidence in the company's ongoing return to growth, highlighting the progress made despite the variability in business performance from period to period.
CSBR's financial metrics reveal a price-to-earnings (P/E) ratio of approximately 44.63, indicating that investors are willing to pay about 44.63 times the company's earnings over the past twelve months. The price-to-sales ratio stands at 2.50, suggesting that the market values the company at 2.5 times its annual sales. The enterprise value to sales ratio is slightly lower at 2.43, reflecting the company's valuation in relation to its sales, including debt and excluding cash.
